Lentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1
US9987351B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 27, 2015 |
| Grant date | Jun 5, 2018 |
| Priority date | — |
| Expiry date | Jan 27, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions, methods, and uses employing lentiviral vector particles for induction of an immune response by administration to a human, wherein the lentiviral vector particles comprise a lentiviral vector, wherein the DNA of the lentiviral vector comprises a promoter directing expression of a HTLV-1 p12p30-Tax-HBZ fusion protein. The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.